IMFINZI (Durvalumab) is a form of immunotherapy and blocks the activity of programmed death-ligand 1 (PDL-1), a molecule found on T cells that suppress immune activity. By blocking PDL-1, T-cells function better and the immune response is stimulated to find and kill cancer cells.
Durvalumab is used to treat;
| Trade Name | IMFINZI |
|---|---|
| Generic Name | Durvalumab |
| Manufacturer | AstraZeneca Pharmaceuticals LP |
| Drug Type | Oncology |
| Indication | Urinary Bladder / Lung cancer |
| Doasage Form | Injectible |
| Packaging | 1 x 2.3ml / 120mg (50mg/ml) |
